STAAR Surgical (NASDAQ:STAA) Receives Equal Weight Rating from Stephens

Stephens reissued their equal weight rating on shares of STAAR Surgical (NASDAQ:STAA) in a report issued on Tuesday,Benzinga reports. Stephens currently has a $17.00 price target on the medical instruments supplier’s stock.

A number of other research firms have also weighed in on STAA. BTIG Research lowered shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research note on Thursday, February 27th. Mizuho lowered STAAR Surgical from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $45.00 to $17.00 in a research note on Wednesday, February 12th. Jefferies Financial Group downgraded STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. Finally, Stifel Nicolaus cut their target price on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $25.29.

STAAR Surgical Trading Up 3.8 %

STAAR Surgical stock opened at $18.28 on Tuesday. The business’s 50 day simple moving average is $20.18 and its 200 day simple moving average is $25.92. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $52.68. The company has a market cap of $901.66 million, a price-to-earnings ratio of -44.59 and a beta of 0.66.

Insider Buying and Selling

In other news, major shareholder Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock in a transaction on Wednesday, February 12th. The stock was acquired at an average cost of $14.96 per share, for a total transaction of $3,883,855.36. Following the purchase, the insider now owns 11,137,623 shares in the company, valued at $166,618,840.08. This trade represents a 2.39 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have acquired 834,343 shares of company stock valued at $13,653,542 over the last quarter. Corporate insiders own 1.00% of the company’s stock.

Institutional Trading of STAAR Surgical

Institutional investors and hedge funds have recently modified their holdings of the business. Broadwood Capital Inc. boosted its holdings in STAAR Surgical by 0.7% in the fourth quarter. Broadwood Capital Inc. now owns 10,848,631 shares of the medical instruments supplier’s stock worth $263,513,000 after purchasing an additional 80,200 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of STAAR Surgical by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock worth $142,232,000 after purchasing an additional 319,441 shares during the period. State Street Corp increased its stake in shares of STAAR Surgical by 0.5% in the third quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier’s stock worth $72,092,000 after purchasing an additional 10,430 shares in the last quarter. Resona Asset Management Co. Ltd. purchased a new position in shares of STAAR Surgical during the 4th quarter valued at $36,411,000. Finally, Geode Capital Management LLC boosted its holdings in STAAR Surgical by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock worth $43,641,000 after buying an additional 31,212 shares during the period. Institutional investors own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.